source
- FDA issues complete response letter rejecting Summit Therapeutics' lung cancer drugThe U.S. Food and Drug Administration released a complete response letter that rejects Summit Therapeutics' lung cancer candidate, providing the agency’s detailed reasons for the decision. The age…
- Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater ChinaPfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…